Clinical Trial

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.
Protocol Amendment History 2 changes
critical Trial completed 2026-03-31
minor Completion moved earlier: 2026-07-04 -> 2026-02-27 2026-03-31
Trial Details
NCT Number NCT07074327
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Enrollment 74 participants
Start Date 2025-07-11
Primary Completion 2026-02-20 (estimated)
Study Completion 2026-02-27 (estimated)
Updated on ClinicalTrials.gov 2026-03-30